COMP <GO>
PTGX vs LLY // REVENUE GROWTH (YOY)
Protagonist Therapeutics Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: PTGX 2
— LLY 12
▲ REVENUE GROWTH (YOY) LEADER: LLY
LAST: $144.85 (+0.35%) • MKT CAP: $9.34B
revenue-growth
0.00%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
revenue-growth
45.51%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PTGX VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PTGX | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 83.64% | -42.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -16.70% | 32.36% | -49.06 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.60% | 2.30% | -1.70 | LLY | /fcf-yield <GO> |
| Operating Margin | -6.00% | 40.21% | -46.21 | LLY | /operating-margins <GO> |
| Net Profit Margin | -5.00% | 31.90% | -36.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 0.00% | 45.51% | -45.51 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 9.29 | +16.71 | PTGX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.77% | +0.13 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.9 | 77.9 | -19.97 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 0.51 | +0.48 | PTGX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.0x | 26.3x | +4.75 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.34B | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PTGX REV | LLY REV | PTGX GROSS % | LLY GROSS % | PTGX FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $65.18B | — | 83.0% | $56.1M | $16.81B |
| FY 2024 | $0 | $45.04B | — | 81.3% | $182.8M | $8.82B |
| FY 2023 | $0 | $34.12B | — | 79.3% | -$70.2M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PTGX // BETA 0.99
LLY // BETA 0.51